GlassScriptPhysician profile
Thomas W Murphy
NPI 1356986558
$7,845.31
in general payments reported to CMS, 2019-2025
43 companies · $1,020 in 2025
The $1,020 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,898 · 2022: $1,753 · 2023: $1,595 · 2024: $1,579 · 2025: $1,020.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,194.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,052.10 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,035.70 | 2021-2025 | |
| Lilly USA, LLC | $784.28 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $717.63 | 2021-2025 | |
| Glaxosmithkline, LLC. | $587.93 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $422.67 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Takeda Pharmaceuticals U.S.A., INC. | $375.18 | 2021-2025 | Trintellix, Eohilia |
| Biohaven Pharmaceutical Holding Company LTD. | $290.60 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $278.55 | 2021-2024 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $234.24 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Biohaven Pharmaceuticals, INC. | $230.46 | 2021 | |
| Amgen INC. | $209.98 | 2021-2025 | Otezla, Repatha, Otezla |
| Exact Sciences Corporation | $199.49 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $139.70 | 2023-2024 | Veozah |
| Amarin Pharma, INC. | $128.97 | 2021 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $118.31 | 2023-2024 | Unithroid |
| Mylan Specialty L.P. | $109.56 | 2022-2024 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $96.83 | 2021-2025 | Airsupra |
| Bausch Health US, LLC | $82.70 | 2021-2024 | Aplenzin, Wellbutrin |
| Kowa Pharmaceuticals America, INC. | $67.52 | 2021 | |
| Antares Pharma, INC. | $67.49 | 2022-2023 | Nocdurna, Xyosted, Tlando |
| Idorsia Pharmaceuticals US INC | $51.81 | 2022-2024 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $51.02 | 2023-2024 | Austedo Xr, Ajovy |
| Tolmar, INC. | $48.69 | 2024-2025 | Jatenzo |
| Axsome Therapeutics, INC. | $43.63 | 2022-2023 | Auvelity |
| Lundbeck LLC | $40.85 | 2024-2025 | Vyepti |
| Janssen Pharmaceuticals, INC | $37.16 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $33.48 | 2024 | Rexulti |
| Phadia US INC. | $32.69 | 2021-2022 | |
| Clarus Therapeutics INC. | $31.66 | 2021 | |
| Corcept Therapeutics | $26.54 | 2025 | Korlym |
| Alnylam Pharmaceuticals INC. | $23.59 | 2024 | Givlaari |
| Sumitomo Pharma America, INC. | $23.59 | 2025 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.92 | 2025 | Caplyta |
| Arbor Pharmaceuticals, INC. | $21.10 | 2021 | |
| Sanofi-Aventis U.S. LLC | $18.88 | 2021 | |
| Phathom Pharmaceuticals, INC. | $18.63 | 2024 | Voquezna |
| Baxter Healthcare | $18.05 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Genentech USA, INC. | $15.83 | 2021 | |
| Halozyme INC | $15.59 | 2023 | |
| Shield Therapeutics INC | $13.83 | 2023 | Accrufer |
| Paratek Pharmaceuticals, INC. | $13.41 | 2024 | Nuzyra |
| Corium, LLC | $12.47 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.